Med. Pro Praxi 2009; 6(1)

Repetitorium Bolest

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Repetitorium Bolest. Med. praxi. 2009;6(1):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Oxford league table of analgesics in acute pain. [on line] 2008. Dostupná z WWW: http://www.jr2.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/Leagtab.html.
    2. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. Journal of Clinical Epidemiology 1998; 51: 1357-1365. Go to original source... Go to PubMed...
    3. Angst MS, Clark JD. Opioid-induced hyperalgesia - A qualitative systematic review. Anesthesiology 2006; 104: 570-587. Go to original source... Go to PubMed...
    4. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association. Circulation 2007; 115: 1634-1642 Dostupný také na WWW: http://circ.ahajournals.org/cgi/content/full/115/12/1634. Go to original source... Go to PubMed...
    5. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology 2006; 13: 1153-1169. Dostupný také na WWW: http://www.guideline.gov/summary/summary.aspx?doc_id=10472&nbr=5495&ss=6&xl=999. Go to original source... Go to PubMed...
    6. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. European Journal of Pain 2006; 10: 287-333. Go to original source... Go to PubMed...
    7. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113: 1578-1587. Go to original source... Go to PubMed...
    8. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 2007; 27: 1219-1230. Go to original source... Go to PubMed...
    9. Eisenberg E, Marinangeli F, Birkhahn J, Paladini A, Varrassi G. Time to modify the WHO analgesic ladder? Pain Clinical Updates 2005; 13: 1-4 Dostupný také na WWW: http://www.iasp-pain.org/AM/AMTemplate.cfm?Section=Home&CONTENTID=2266&TEMPLATE=/CM/ContentDisplay.cfm.
    10. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults - Results of a US consensus panel of experts. Archives of Internal Medicine 2003; 163: 2716-2724. Go to original source... Go to PubMed...
    11. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. British Medical Journal 2006; 332: 1302-1305. Go to original source... Go to PubMed...
    12. Kozák J, Lejčko J, Kršiak M. Farmakoterapie chronické nenádorové bolesti. Doporučený postup. 2004. Dostupný také z WWW: http://www.svl.cz/Files/public/svl/Dp_2004/Farmakoterapie_Bolesti.pdf.
    13. Kršiak M, Kozák J, Lejčko J, Skála B. Farmakoterapie akutní bolesti. Doporučený postup. 2004. Dostupný také z WWW: http://www.svl.cz/Files/public/svl/Dp_2004/Farmakoterapie_Bolesti.pdf.
    14. Málek J, Príkazský V, Dáňová J, Kurzová A, Kozák J, Lengálová E. Výskyt bolesti v populaci České republiky - pilotní studie. Bolest 2003; 6: 113-122.
    15. Marková J, Skála B, Keller O, Mastík J, Konštacký S, Waberžinek G. Bolesti hlavy. Doporučený postup 2007. Dostupný také z WWW: http://www.svl.cz/Files/nastenka/page_4766/Version1/Bolesti-hlavy.pdf.
    16. McNicol E. Opioid side effects. Pain Clinical Updates 2007; 15: 1-6 Dostupný také na WWW: http://www.iasp-pain.org/AM/AMTemplate.cfm?Section=Home&TEMPLATE=/CM/ContentDisplay.cfm&CONTENTID=3852.
    17. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine 2005; 352: 1081-1091. Go to original source... Go to PubMed...
    18. Pavelka K. Léčba bolesti u osteoartrózy. Bolest 2006; 9: 20. EULAR doporučený postup je dostupný na WWW: http://ard.bmj.com/cgi/content/full/64/5/669.
    19. Prescott LF. Paracetamol, alcohol and the liver. Br. J. Clin. Pharmacol. 2000; 49: 291-301. Go to original source... Go to PubMed...
    20. Rokyta R. Bolest zad. Plzeň: Adéla - grafické studio 2008. v tisku.
    21. Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract - Indigestion and non-steroidal antiinflammatory drugs. British Medical Journal 2001; 323: 1236-1239. Go to original source... Go to PubMed...
    22. Seifert B, Dítě P, Bureš J, Pavelka K, Forejtová Š, Hep A, Jirásek V, Koudelka T, Lukáš K, Štolfa J, Vencovský J, Vojtíšková J. Rizika a prevence nežádoucích účinků nesteroidních antiflogistik a kyseliny acetylsalicylové. Mezioborové konsenzuální doporučení pro praktické lékaře. Prakt. Lék. 2006; 86: 38-42.
    23. Ševčík P, Málek J, Bejšovec D, Gabrhelík T, Křikava I, Lejčko J, Mach D, Mixa V, Vojtíšková M. Léčba akutní pooperační bolesti. Doporučený postup. 2008 Dostupný z WWW: http://www.pain.cz/file-content/Bolest_CSARIM_130308_1_.pdf.
    24. Sláma O. Mírnění bolestí u umírajících nemocných. Klin Farmakol Farm 2007; 21: 59-61.
    25. Sláma O, Vorlíček J, Ševčík P, Hakl M, Doležal T. Farmakoterapie chronické nádorové bolesti. Doporučený postup 2004. Dostupný z WWW: http://www.svl.cz/Files/nastenka/page_4766/Version1/Farmakoterapie-bolesti.pdf.
    26. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily - A randomized controlled trial. Jama-Journal of the American Medical Association 2006; 296: 87-93. Go to original source... Go to PubMed...
    27. ##
    28. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview IL: American Pain Society, 2003.
    29. APS Congress, 20.-23. 3. 2003. American Pain Society, Chicago, USA.
    30. Doležal T, Hakl M, Kozák J et al. Metodické pokyny pro farmakoterapii bolesti UPDATE Bolest 2006; Suppl 9: 7-25.
    31. Eisenberg K, et al. Time to Modify the WHO Analgesic Ladder? In: Pain Clinical Updates IASP, Volume XIII., No. 5; 2007.
    32. Cherny NI, Portenoy RK. In: Wall PD, Melzack R (Eds). Textbook of Pain, 4th ed. London: Churchill Livingstone, 1999, pp.1479-1522.
    33. McQuay H. Lancet 1999; 353: 2229-2232.
    34. Mercadante S, et al. Support Care Cancer 2001; 9: 205-206.
    35. Morita T, et al. J. Pain Symptoms Management 2005; 30: 96-103. Go to original source... Go to PubMed...
    36. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst. Rev 2006; 4.
    37. Rokyta R, Kršiak M, Kozák J. Bolest 2006; 100-167.
    38. ##
    39. Doležal T, Hakl M, Kozák J, et al. Metodické pokyny pro farmakoterapii akutní a chronické nenádorové bolesti. Farmakoterapie 2006; 3: 287-296.
    40. ##
    41. Češková E. Duálně působící antidepresiva. Remedia 2006; 16: 594-597.
    42. Diener H. Established treatment strategies for varying clinical situations. The 13th Congress of the IHS 2007, Stockholm, Sweden.
    43. Dočekal P, Keller O, Marková J, Opavský J. Bolesti hlavy. In: Rokyta R, Kršiak M, Kozák J (Eds). Bolest. Praha: Tigis, 2006: 461-476.
    44. Doležal T, Slíva J. Nimesulidum. Remedia 2004; 14: 2-10.
    45. Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. European Journal of Neurology 2006; 13: 560-572. Go to original source... Go to PubMed...
    46. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675. Go to original source... Go to PubMed...
    47. Ho TW, Ferrari M, Dodick DW, et al. Acute antimigraine efficacy and tolerability of novel oral CGRP antagonist MK-0974, a phase III clinical trial versus placebo and zolmitriptan. European Headache and Migraine Trust International Congress 2008, London, UK.
    48. Mastík J. Specifická léčba migrény. Interní Med. 2007; 4: 188-191.
    49. Niedermayerová I, Mastík J. Lisinopril je účinný v profylaxi migrény. Practicus. 2007; 5-6: 200-203.
    50. Opavský J, Doležil D, Mastík J, Marková J, Grünermelová M, Niedermayerová I, Rejda J, Dočekal P, Opavská H. Comparison between migraine treatment by headache specialists and primary care physicians in the Czech republic. Cephalalgia. 2007; 27: 652-653.
    51. Peatfield P. Dodick DW. Headaches. Oxford: Fine Print, 2002: 176-201.
    52. Rainsford KD. Current status of the therapeutic uses and actions of the preferential cyklo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006; 14: 120-137. Go to original source... Go to PubMed...
    53. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headaches in a general population. J Clin Epidemiol. 1991; 44: 1147-1157. Go to original source... Go to PubMed...
    54. Relja G, Granato A, Antonello RD, Zorzon M. Headache Induced by Chronic Substance Use: Analysis of Medication Overused and Minimum Dose Required to Induce Headache. Headache 2004; 44: 148-153. Go to original source... Go to PubMed...
    55. Slíva J, Doležal T, Kršiak M. Přehled analgetik. Praha: Tigis, 2004.
    56. Stratified Care vs Step Care Strategies for migraine. The Disability in Strategies of care (DISC) Study: Randomised Trial. JAMA. 2000; 284; 2599-2605. Go to original source... Go to PubMed...
    57. The International Classification of Headache Disorders. 2nd Edition, Cephalgia 2003; 24(Suppl 1/24): 1-160.
    58. Waberžinek G. Bolesti hlavy. Praha: Triton, 2000: 66-116.
    59. ##
    60. Bigal EB, Tepper ST, Sheftell FD, Rapoport AM, Lipton RB. Chronic Daily Headache: Correlation Between the 2004 and the 1988 International Headache Society Diagnostic Criteria. Headache 2004; 44: 684-691.
    61. Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. European Journal of Neurology 2006; 13: 560-572. Go to original source... Go to PubMed...
    62. Grazzi L, Andrasik F, Amico D, Usai S, Kass S, Bussone G. Disability in Chronic Migraine patients With Medication Overuse: Treatment Effects at 1-Year Follow-up. Headache 2004; 44: 678-683. Go to original source... Go to PubMed...
    63. Hagen K, Albretsen C, Vilming ST, Salvesen R, Gronning M, et al. Managment of medication overuse headache: 1-year randomized open-label trial. Cephalalgia 2009; 2: 221-232. Go to original source... Go to PubMed...
    64. Katsarava Z, Muessig, Dzagnidze A, Fritsche G, Diener HC. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2004; 25: 12-15. Go to original source... Go to PubMed...
    65. Mastík J. Migréna - nová mezinárodní klasifikace a moderní léčebné postupy. Neurol pro praxi 2004; 2: 79-83.
    66. Marková J. Komorbidity migrény. Neurol pro praxi 2005; 5: 248-250.
    67. Relja G, Granato A, Antonello RD, Zorzon M. Headache Induced by Chronic Substance Use: Analysis of Medication Overused and Minimum Dose Required to Induce Headache. Headache 2004; 44: 148-153. Go to original source... Go to PubMed...
    68. Saper JR, Dodick D, Gladstone JP. Management of Chronic Daily Headache: Challenges in Clinical Practice. Headache 2005; 45(Suppl 1): 74-85. Go to original source... Go to PubMed...
    69. Silberstein DS, Lipton BR, Dalessio JD. Wolff´s Headache and Other Head Pain. New York: Oxford University Press 2001: 247-282.
    70. The International Classification of Headache Disorders 2nd Edition. Cephalalgia 2004; 24(Suppl 1): 1-160.
    71. Waberžinek G. Bolesti hlavy. Praha: Triton, 2000: 156-162.
    72. ##
    73. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust. N Z Y Med 1987; 17: 301-304. Go to original source... Go to PubMed...
    74. Arellano F, Sacristen JA. Allopurinol hypersensitivity syndromme: a review. Ann Pharmacother 1993; 27: 337-343. Go to original source... Go to PubMed...
    75. Arromdee E, Michet CJ, Croowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 2403-2406. Go to PubMed...
    76. Becker MA, Schumacher HR, Wortman RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthinoxidase. A twenty-eight-day, multicenter, phase II., randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005; 52: 916-923. Go to original source... Go to PubMed...
    77. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102. Go to original source... Go to PubMed...
    78. Cannon DC, Curtis SP, Garret A, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with OA and RA in the Multinational Etoricoxib and Diclofenac Arthritis Long Term (MEDAL) programme: a randomised conparison. Lancet 2006; 368: 1771-1781. Go to original source... Go to PubMed...
    79. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43: 103-108. Go to original source...
    80. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006; 8(Suppl 1): S 3. Go to original source... Go to PubMed...
    81. Emmerson BT. The managment of gout. N Engl J Med 1996; 334: 445-451. Go to original source... Go to PubMed...
    82. Fernandez C, Noguera R, Gonzales JA, et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolon acetonide. J Rheumatol 1999; 26: 2285-2286. Go to PubMed...
    83. Goldman S. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003; 3: 89-93. Go to original source... Go to PubMed...
    84. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1227-1281. Go to original source... Go to PubMed...
    85. Choi HK, Atkinson K, Karlson EW, et al. Purine - rich foods, dairy and protein intake, and risk of gout in men. N Engl J Med 2004; 350: 1093-1103. Go to original source... Go to PubMed...
    86. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6: 489-504. Go to original source... Go to PubMed...
    87. Madsen TE, Mullestein JB, Carlquist JF. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrology 2005; 25: 45-49. Go to original source... Go to PubMed...
    88. Martinon F, Petrili V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP 3 inflammasone. Nature 2006. Go to original source...
    89. Pascual E, Sinera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007; 19: 122-127. Go to original source... Go to PubMed...
    90. Schumacher HR, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1482-1482. Go to original source... Go to PubMed...
    91. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity of drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomised, controlled trial. J Am Med Assoc 2000; 284: 1247-1249. Go to original source... Go to PubMed...
    92. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-1104. Go to original source... Go to PubMed...
    93. Sundy JS, Becker MA, Baraf HSB, et al. A phase II. study of multiple doses of intravenous polyethylene glycol (PEG) - uricase in patients with hyperuricemia and refractory gout. Arthritis Rheum 2005; 52: S679.
    94. Torumm M, Yardim S, Simsek B, et al. Serum uric acid levels in cardiovascular diseases. J Clin Pharm Ther 1998; 23: 25-29. Go to original source... Go to PubMed...
    95. Yoo WT, Sung KCH, Skin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933. Go to original source... Go to PubMed...
    96. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900. Go to original source... Go to PubMed...
    97. Werhen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal - induced arthritis: an effective alternative to NSAIDs. Rev Rheum Engl Ed 1996; 63: 248-254.
    98. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I. Diagnosis: Report of task force of the ESCISIT. Ann Rheum Dis 2006; doi: 10.1136/ard.2006.055251. Go to original source... Go to PubMed...
    99. ##
    100. Likar R. In: Likar R. Practice of transdermal pain therapy. Bremen: UNI-MED 2005: 160 s.
    101. Friderichs E, Kőgel B, Christov T. Interaction of buprenorfin with other ? agonists. Prague: EFIC 2003.
    102. Lejčko J, Machart S, et al. Dlouhodobá léčba opioidy u chronické nenádorové bolesti. Bolest 2003; 3: 146-154.
    103. Han A, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322: 1-7. Go to original source... Go to PubMed...
    104. Megens AA, et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998; 15(4): 253-258. Go to original source... Go to PubMed...
    105. Payne R, Chandler S. Guidelines for the clinical use of transdermal fentanyl; Anti-Cancer Drugs 2003; 6(Suppl 3): 50-53. Go to original source... Go to PubMed...
    106. Donner B, Zenz M, et al. Fentanyl - TTS for postoperative pain therapy. A new alternative? Anaesthesist 1993; 42: 309-315. Go to PubMed...
    107. Morita T, Takigawa CH, et al. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage 2005; 30(1): 96-103. Go to original source... Go to PubMed...
    108. Radbruch L, Sabatovski R, et al. Transdermal fentanyl for the management of cancer pain - a survey of 1005 patients. Palliative Medicine 2001; 15: 309-321. Go to original source... Go to PubMed...
    109. Ripamonti C, Campa T, De Cono F. Withdrawal symptoms during chronic transdermal fentanyl administration managed with oral methadone. J Pain Symptom Manage 2004; 27(3): 191-195. Go to original source... Go to PubMed...
    110. Budd K. Buprenorfin - A - review. Evidence based medicine in practice 2002: 1-3.
    111. Sittl R, Nuiten M. Paulsen Nautrup BP Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorfine during teratment of patients with cancer a noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005; 27(7): 1022-1031. Go to original source... Go to PubMed...
    112. Metodické pokyny pro farmakoterapii bolesti. Bolest 2004; 7(Suppl 1): 1-20.
    113. Griessinger N, Sittl R, Likar R. Transdermal buprenorfin in clinical practice a postmarketing surveillance study in 13 179 patients. Curr Med res Opin 2005; 201(8): 1147-1156. Go to original source... Go to PubMed...
    114. Davis MP. Buprenorphine in cancer pain. Support Cancer 2005; 13(11): 878-887. Go to original source... Go to PubMed...
    115. Gal TJ Naloxon reversal of buprenorphine-induced respiration depression. Clin Pharm Ther 1989; 45(1): 66-71.
    116. ##
    117. Hassenbusch SJ, Portenoy RK, Cousins M, Buchser E, et al. Polyanalgesic Consensus Conference 2003:An update management of pain by intraspinal drug delivery. J Pain Symptom Manage 2004; 27(6): 540-563. Go to original source... Go to PubMed...
    118. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93(3): 247-257. Go to original source... Go to PubMed...
    119. Sláma O, Vondráčková D, Vorlíček J, Urgošík D. Symptomatická léčba nádorové bolesti. In: Rokyta R, Kršiak M, Kozák J. Bolest. Praha: Tigis, 2006: 378-382.
    120. Sloan P, Basta M, Storey P, von Gunten Ch. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain; Anesth Analg 1999; 89: 760-761. Go to original source... Go to PubMed...
    121. Stute P, Soukup J, Menzel M, et al. Analysis and treatment of different types of neuropathic cancer pain. J Pain Symptom Manage 2003; 26(6): 1123-1131. Go to original source... Go to PubMed...
    122. Thomas J, Kronenberg R, Cox MC, et al. Intravenous lidocain relieves severe pain: result of inpatient hospice chart review. J Pain Symptom Manage 2004; 7(5): 660-667. Go to original source...
    123. Votava M, Doležal T, Kozák J, Vondráčková D. Adjuvantní léčiva v terapii bolesti, in Rokyta R, Kršiak M, Kozák J, Bolest; Tigis Praha 2006: 147-156.
    124. WHO Technicals Report Series, No. 804, 2nd edition. WHO, 1996.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.